(SOLV) Solventum - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 13.005m USD | Total Return: 1.8% in 12m

Wound Care, Dental Supplies, Healthcare Software, Surgical Tools
Total Rating 48
Safety 70
Buy Signal -0.10
Medical Instruments & Supplies
Industry Rotation: +2.0
Market Cap: 13.0B
Avg Turnover: 114M
Risk 3d forecast
Volatility26.1%
VaR 5th Pctl4.46%
VaR vs Median3.62%
Reward TTM
Sharpe Ratio0.04
Rel. Str. IBD34.1
Rel. Str. Peer Group59.1
Character TTM
Beta0.648
Beta Downside0.453
Hurst Exponent0.533
Drawdowns 3y
Max DD39.97%
CAGR/Max DD-0.09
CAGR/Mean DD-0.22
EPS (Earnings per Share) EPS (Earnings per Share) of SOLV over the last years for every Quarter: "2021-12": null, "2022-03": null, "2022-06": null, "2022-09": null, "2022-12": null, "2023-03": null, "2023-06": null, "2023-09": null, "2023-12": 2.31, "2024-03": 2.08, "2024-06": 1.56, "2024-09": 1.64, "2024-12": 1.41, "2025-03": 1.34, "2025-06": 1.69, "2025-09": 1.5, "2025-12": 1.57, "2026-03": 1.48,
EPS CAGR: -17.95%
EPS Trend: -61.0%
Last SUE: 0.70
Qual. Beats: 0
Revenue Revenue of SOLV over the last years for every Quarter: 2021-12: 8171, 2022-03: 2058, 2022-06: 2058, 2022-09: 2009, 2022-12: 1970, 2023-03: 2011, 2023-06: 2076, 2023-09: 2074, 2023-12: 2036, 2024-03: 2016, 2024-06: 2081, 2024-09: 2082, 2024-12: 2075, 2025-03: 2070, 2025-06: 2161, 2025-09: 2096, 2025-12: 1998, 2026-03: 2007,
Rev. CAGR: -0.67%
Rev. Trend: 29.0%
Last SUE: 2.06
Qual. Beats: 4

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Description: SOLV Solventum

Solventum Corporation (SOLV) is a diversified healthcare technology company organized into three primary operating segments: MedSurg, Dental Solutions, and Health Information Systems. The company’s portfolio ranges from physical medical supplies, such as advanced wound care and orthodontic products, to software-driven clinical documentation and coding automation platforms.

Operating within the Health Care Equipment sector, Solventum utilizes a multi-channel commercial model that includes direct-to-consumer sales, e-commerce, and specialized distribution networks. This sector is characterized by high research and development costs and rigorous regulatory oversight, which often create significant barriers to entry for new competitors.

The company was established as an independent entity in 2023 following its spin-off from 3M, inheriting a global infrastructure that serves both clinical providers and original equipment manufacturers. Investors can further analyze the companys valuation metrics and historical performance data on ValueRay.

Headlines to Watch Out For
  • Medsurg segment performance hinges on global surgical volume and advanced wound care adoption
  • Dental Solutions revenue tied to discretionary consumer spending on orthodontics and restorative procedures
  • Health Information Systems growth depends on hospital adoption of AI-driven coding automation
  • Post-spin-off debt reduction and operational efficiency improvements influence investor sentiment and valuation
Piotroski VR‑10 (Strict) 5.5
Net Income: 1.43b TTM > 0 and > 6% of Revenue
FCF/TA: -0.01 > 0.02 and ΔFCF/TA -4.09 > 1.0
NWC/Revenue: 2.87% < 20% (prev 5.86%; Δ -2.99% < -1%)
CFO/TA 0.01 > 3% & CFO 151.0m > Net Income 1.43b
Net Debt (4.52b) to EBITDA (2.76b): 1.64 < 3
Current Ratio: 1.07 > 1.5 & < 3
Outstanding Shares: last quarter (175.5m) vs 12m ago 0.40% < -2%
Gross Margin: 53.67% > 18% (prev 0.55%; Δ 5.31k% > 0.5%)
Asset Turnover: 57.73% > 50% (prev 57.19%; Δ 0.54% > 0%)
Interest Coverage Ratio: 6.55 > 6 (EBITDA TTM 2.76b / Interest Expense TTM 305.0m)
Altman Z'' 1.60
A: 0.02 (Total Current Assets 3.58b - Total Current Liabilities 3.35b) / Total Assets 14.10b
B: 0.13 (Retained Earnings 1.81b / Total Assets 14.10b)
C: 0.14 (EBIT TTM 2.00b / Avg Total Assets 14.31b)
D: 0.13 (Book Value of Equity 1.14b / Total Liabilities 9.13b)
Altman-Z'' Score: 1.60 = BB
Beneish M -3.01
DSRI: 0.96 (Receivables 1.06b/1.11b, Revenue 8.26b/8.31b)
GMI: 1.02 (GM 53.67% / 54.59%)
AQI: 0.90 (AQ_t 0.64 / AQ_t-1 0.71)
SGI: 0.99 (Revenue 8.26b / 8.31b)
TATA: 0.09 (NI 1.43b - CFO 151.0m) / TA 14.10b)
Beneish M-Score: -3.01 (Cap -4..+1) = AA
What is the price of SOLV shares? As of May 16, 2026, the stock is trading at USD 74.26 with a total of 1,663,076 shares traded.
Over the past week, the price has changed by +1.20%, over one month by +7.47%, over three months by +0.72% and over the past year by +1.81%.
Is SOLV a buy, sell or hold? Solventum has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold SOLV.
  • StrongBuy: 1
  • Buy: 2
  • Hold: 8
  • Sell: 1
  • StrongSell: 0
What are the forecasts/targets for the SOLV price?
Analysts Target Price 81.1 9.2%
Solventum (SOLV) - Fundamental Data Overview as of 14 May 2026
P/E Trailing = 9.1922
P/E Forward = 11.3636
P/S = 1.5741
P/B = 2.5569
P/EG = 1.2198
Revenue TTM = 8.26b USD
EBIT TTM = 2.00b USD
EBITDA TTM = 2.76b USD
Long Term Debt = 4.58b USD (from longTermDebt, last quarter)
Short Term Debt = 505.0m USD (from shortTermDebt, last quarter)
Debt = 5.08b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.52b USD (from netDebt column, last quarter)
Enterprise Value = 17.52b USD (13.01b + Debt 5.08b - CCE 561.0m)
Interest Coverage Ratio = 6.55 (Ebit TTM 2.00b / Interest Expense TTM 305.0m)
EV/FCF = -86.33x (Enterprise Value 17.52b / FCF TTM -203.0m)
FCF Yield = -1.16% (FCF TTM -203.0m / Enterprise Value 17.52b)
FCF Margin = -2.46% (FCF TTM -203.0m / Revenue TTM 8.26b)
Net Margin = 17.33% (Net Income TTM 1.43b / Revenue TTM 8.26b)
Gross Margin = 53.67% ((Revenue TTM 8.26b - Cost of Revenue TTM 3.83b) / Revenue TTM)
Gross Margin QoQ = 54.66% (prev 49.30%)
Tobins Q-Ratio = 1.24 (Enterprise Value 17.52b / Total Assets 14.10b)
Interest Expense / Debt = 1.22% (Interest Expense 62.0m / Debt 5.08b)
Taxrate = 18.75% (3.00m / 16.0m)
NOPAT = 1.62b (EBIT 2.00b * (1 - 18.75%))
Current Ratio = 1.07 (Total Current Assets 3.58b / Total Current Liabilities 3.35b)
Debt / Equity = 1.02 (Debt 5.08b / totalStockholderEquity, last quarter 4.97b)
Debt / EBITDA = 1.64 (Net Debt 4.52b / EBITDA 2.76b)
 Debt / FCF = -22.26 (negative FCF - burning cash) (Net Debt 4.52b / FCF TTM -203.0m)
 Total Stockholder Equity = 4.66b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.01% (Net Income 1.43b / Total Assets 14.10b)
RoE = 30.71% (Net Income TTM 1.43b / Total Stockholder Equity 4.66b)
RoCE = 21.64% (EBIT 2.00b / Capital Employed (Equity 4.66b + L.T.Debt 4.58b))
RoIC = 15.57% (NOPAT 1.62b / Invested Capital 10.43b)
WACC = 6.22% (E(13.01b)/V(18.09b) * Re(8.26%) + D(5.08b)/V(18.09b) * Rd(1.22%) * (1-Tc(0.19)))
Discount Rate = 8.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.39 | Cagr: 0.71%
 [DCF] Fair Price = unknown (Cash Flow -203.0m)
 EPS Correlation: -60.99 | EPS CAGR: -17.95% | SUE: 0.70 | # QB: 0
Revenue Correlation: 29.00 | Revenue CAGR: -0.67% | SUE: 2.06 | # QB: 4
EPS current Quarter (2026-06-30): EPS=1.90 | Chg30d=+14.40% | Revisions=+20% | Analysts=10
EPS next Quarter (2026-09-30): EPS=1.43 | Chg30d=-15.01% | Revisions=+50% | Analysts=10
EPS current Year (2026-12-31): EPS=6.54 | Chg30d=+1.12% | Revisions=+62% | GrowthEPS=+7.0% | GrowthRev=-1.5%
EPS next Year (2027-12-31): EPS=7.04 | Chg30d=-0.01% | Revisions=-20% | GrowthEPS=+7.7% | GrowthRev=+3.6%
[Analyst] Revisions Ratio: +62%